Bolt Biotherapeutics, Inc., based in the San Francisco Bay Area, is a publicly-traded biotechnology company developing Boltbody™ Immune-stimulating Antibody Conjugates (ISAC), a new class of immuno-oncology therapeutics that have eliminated tumors following systemic administration in preclinical studies and results in the development of immunological memory, which may lead to more durable clinical responses for patients. 

Biotechnology

Bolt Biotherapeutics

Randall Schatzman

Murray Nguyen

Christine Gustin

Samara Violet

Jason Ptacek

Jenny Yuan

Seth M.

Lindsey Gourley

Anthony Wong

Kristi Balacy

Arthur Lee

Husein Hadeiba

Coya Tapia

Dawn Colburn

Willie Quinn

Lynn Ferguson Lewis

Pam Howland

Nathan Ihle

Grant Yonehiro

Michael N. Alonso

Wesley Burwell

Lu Xu

Sarah Nemec

The Clinical Development and Research team at Bolt Biotherapeutics is responsible for designing and executing clinical trials to evaluate the safety and efficacy of Boltbody™ Immune-stimulating Antibody Conjugates (ISAC) in treating tumors. This multidisciplinary team collaborates closely on translational medicine, toxicology, and analytical development, aiming to advance innovative therapies from preclinical studies to human applications and ultimately improve patient outcomes in immuno-oncology.

Clinical Development and Research

Leadership Team

Laboratory Operations and Quality Control

Clinical Development and Research

About

Team members

Other teams at Bolt Biotherapeutics

Leadership Team

Laboratory Operations and Quality Control